Company intelligence / Profile preview

T3 Pharmaceuticals

Ownership: Private
Development stage: Phase 1

Overview

T3 Pharmaceuticals developed a proprietary immuno-oncology platform using live, genetically engineered bacteria that selectively colonize solid tumors and deliver therapeutic protein payloads directly into cancer cells. Their approach leverages the natural Type III Secretion System of bacteria for targeted intracellular delivery. The company’s lead program aims to induce highly specific immune responses within tumors. As of November 2023, Boehringer Ingelheim acquired T3 Pharma to expand its immuno-oncology pipeline.

Therapeutic areas: Oncology
Modalities: Live bacteria-based therapeuticsProtein delivery via engineered bacteriaImmune-modulating proteins
Industry: Biotech

Drug pipeline

1 asset

T3P-Y058-739

Partnerships

Now integrated into Boehringer Ingelheim’s R&D network post-acquisition. No other major partnerships disclosed.

Beyond the preview

Go deeper on T3 Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T3 Pharmaceuticals.

Explore the full profile